28254372|t|Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency
28254372|a|Systemic drug delivery to a solid tumor involves a sequence of steps that determine efficacy and survival. Extravasation from circulation at the tumor site is a critical step in this sequence since it regulates how much of the drug accumulates in the tumor. Despite its importance in determining outcomes, extravasation from circulation remains a "black box." The objective of this study is to develop predictive tools for optimization of drug delivery systems. By comparing pharmacokinetics of liposomal doxorubicin in tumor -free and tumor bearing mice we quantitatively assess the rate constants for distribution, elimination, and tumor accumulation. We then relate these rate constants to the tumor -type and drug delivery system. We compare tumor accumulation in three tumor types and show a 10-fold difference between a colorectal adenocarcinoma and a pancreatic adenocarcinoma. Finally, we show how quantitative predictions of changes in tumor accumulation can be used to optimize drug delivery system s.
28254372	0	5	Tumor	T191	C0027651
28254372	6	18	accumulation	T033	C4055506
28254372	22	43	liposomal doxorubicin	T109,T195	C0717726
28254372	53	59	murine	T015	C0026809
28254372	60	66	models	T008	C0599779
28254372	79	87	delivery	T074	C0085104
28254372	88	98	efficiency	T081	C0013682
28254372	108	121	drug delivery	T074	C0085104
28254372	127	138	solid tumor	T191	C0280100
28254372	183	191	efficacy	T080	C1280519
28254372	196	204	survival	T169	C0220921
28254372	206	219	Extravasation	T046	C0015376
28254372	225	236	circulation	T040	C1516559
28254372	244	249	tumor	T191	C0027651
28254372	326	342	drug accumulates	UnknownType	C0678759
28254372	350	355	tumor	T191	C0027651
28254372	405	418	extravasation	T046	C0015376
28254372	424	435	circulation	T040	C1516559
28254372	481	486	study	T062	C0008972
28254372	522	534	optimization	T052	C2698650
28254372	538	559	drug delivery systems	T074	C0085104
28254372	574	590	pharmacokinetics	T039	C0031327
28254372	594	615	liposomal doxorubicin	T109,T195	C0717726
28254372	619	624	tumor	T191	C0027651
28254372	635	640	tumor	T191	C0027651
28254372	649	653	mice	T015	C0026809
28254372	657	678	quantitatively assess	T081	C0034384
28254372	683	697	rate constants	T081	C2986811
28254372	702	714	distribution	UnknownType	C0699903
28254372	716	727	elimination	T040	C0683141
28254372	733	738	tumor	T191	C0027651
28254372	739	751	accumulation	T033	C4055506
28254372	774	788	rate constants	T081	C2986811
28254372	796	801	tumor	T191	C0027651
28254372	812	832	drug delivery system	T074	C0085104
28254372	845	850	tumor	T191	C0027651
28254372	851	863	accumulation	T033	C4055506
28254372	873	878	tumor	T191	C0027651
28254372	925	950	colorectal adenocarcinoma	T191	C1319315
28254372	957	982	pancreatic adenocarcinoma	T191	C0281361
28254372	1005	1029	quantitative predictions	T081	C0034384
28254372	1044	1049	tumor	T191	C0027651
28254372	1050	1062	accumulation	T033	C4055506
28254372	1078	1086	optimize	T052	C2698650
28254372	1087	1107	drug delivery system	T074	C0085104